A comprehensive update on the combination products market shows significant industry partnerships, development challenges, and strategic imperatives for success in the sector characterized by dynamic collaboration between pharmaceutical and device companies, rapid product development cycles, and complex regulatory landscapes.
The future of healthcare depends on cross-sector collaboration among regulatory, commercial, R&D, and business development teams. This integrated approach is crucial to avoiding siloed decisions that could hinder long-term progress. Sustainability must be embedded throughout the product life cycle—from design and manufacturing to distribution and use—ensuring products not only restore sight but also address pressing environmental and logistical challenges.
When hardware and firmware are developed by separate vendors, diagnosing issues like symptoms of non-performance becomes slower and more complex. Unified engineering teams are essential to MedTech success.
Implementing a hybrid work environment with R&D teams yields significant benefits but also presents challenges. In this article, we explore how to achieve successful R&D programs within the context of hybrid environments and share key strategies and best practices to effectively navigate the challenges, including the safeguarding of sensitive information and data.
Medical device regulations change frequently, so companies must be prepared to adapt. Following are strategies organizations can embrace to become more agile, allowing them to thrive amidst these increasingly rapid changes in innovation and regulation.
Healthcare cyberattacks are becoming more common and more costly—both financially and to patient care continuity. Internet-connected IoMT devices and equipment remain a security concern for healthcare delivery organizations. Deeper collaboration between HDOs, medical device manufacturers and security providers is needed to reduce risk and vulnerability.
The goal of the TAP Pilot is to reduce the time from concept to commercialization of medical devices by facilitating robust engagement early in the process with the FDA, industry and key stakeholders.
Building fruitful development partnerships between companies, governments and researchers will enable the most promising and impactful deployments in healthcare.
During this week’s Consumer Electronics Show, FDA Principal Deputy Commissioner Amy Abernathy talks about lessons learned from the pandemic and 2021 goals.
The giant leap forward in virtual health is punctuating the need for reliable, clinically accurate technologies to advance how virtual medicine is delivered.
